The FDA has approved revisions to the safety labeling for zolpidem tartrate, imipenem-cilastatin intramuscular injection, imipenem-cilastatin intravenous infusion, and adefovir dipivoxil. Medscape Medical News
Should immunotherapy should be recognized as the first-line therapeutic treatment for allergic rhinoconjunctivitis? Current Opinion in Allergy and Clinical Immunology
The value of using outcome measures is critically scrutinized in an examination of the debate between rights-oriented and commodity-oriented approaches to healthcare delivery. Medscape General Medicine